News about Market

Tissue Dynamics and Galmed Pharmaceuticals Partner on Cardiac Fibrosis Platform for Aramchol Therapies

Tissue Dynamics and Galmed Pharmaceuticals partner to develop a human-centered cardiac fibrosis platform that will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair.

Market | 07/05/2026 | By News Bureau

Viralgen Partners with Elaaj Bio to Advance Gene Therapy for CDKL5 Deficiency Disorder

Viralgen partners with Elaaj Bio to advance an AAV-based gene therapy program for CDKL5 Deficiency Disorder, leveraging specialised manufacturing expertise.

Market | 06/05/2026 | By News Bureau |  157

Merck Completes USD 5.8 Billion Acquisition of Terns Pharmaceuticals to Strengthen Oncology Pipeline

Merck acquires Terns Pharmaceuticals, advancing development of next-generation therapies for chronic myeloid leukaemia.

Market | 06/05/2026 | By News Bureau |  104

Accord Healthcare US Relaunches Tadalafil Tablets with Expanded Dosage Availability

Accord Healthcare US relaunches Tadalafil tablets with expanded dosage strengths to improve access for treating Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH), including ED/BPH combination therapy.

Market | 05/05/2026 | By News Bureau

Eton Pharmaceuticals Relaunches HEMANGEOL (Propranolol) Oral Solution

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Anovo Specialty Pharmacy distribution and Eton Cares support, improving access to the only FDA-approved treatment for infantile hemangioma.

Market | 05/05/2026 | By News Bureau |  104

US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib

Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.

Market | 04/05/2026 | By News Bureau |  350

Vanda Pharmaceuticals Launches NEREUS (tradipitant) for Motion Sickness in US

Vanda Pharmaceuticals launches NEREUS (tradipitant), the first new motion sickness treatment in over 40 years, now available in the US with direct ordering via nereus.us.

Market | 04/05/2026 | By News Bureau |  135

Novelty Nobility Partners with AGC Biologics to Advance Bispecific Drug Candidate

Novelty Nobility partners with AGC Biologics to advance a bispecific Antibody Drug Candidate (ADC) into GMP manufacturing, showcasing Japan’s bioprocessing expertise and AGC Biologics’ global development network.

Market | 04/05/2026 | By News Bureau

Indoco Remedies Transfers Ophthalmic Division to Sunways India

Indoco Remedies transfers its ophthalmic business in India and select African markets to Sunways India under a strategic business transfer agreement to strengthen portfolio focus and growth.

Market | 02/05/2026 | By News Bureau |  326

BeOne Medicines Secures FDA Priority Review for Tevimbra-Ziihera Combo in HER2 plus Gastroesophageal Cancer

U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.

Market | 01/05/2026 | By News Bureau